Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Launched by GLAUKOS CORPORATION · Nov 22, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new eye cream called Travoprost, which is intended to help lower high pressure inside the eyes for people with open-angle glaucoma or ocular hypertension. Researchers want to find out how safe this cream is and how well it works compared to other treatments. Participants will use different doses of the Travoprost cream and compare its effects to a commonly used eye drop treatment.

To join the study, participants need to be at least 18 years old and have a diagnosis of open-angle glaucoma or ocular hypertension in both eyes. They should also have a certain level of vision and be able to provide consent to participate. If someone has a history of certain heart or lung conditions, or if they are allergic to similar medications, they may not be eligible. Those who participate can expect to receive either the Travoprost cream or other standard treatments while being monitored for safety and effectiveness throughout the trial. This study is currently recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female, 18 years of age or older at the Screening Visit;
• • Willing and able to provide written informed consent on the IRB/IEC-approved informed consent form;
• • Diagnosis of OAG (including pigmentary and pseudoexfoliative) or OHT in both eyes;
• • Qualifying IOP in the study eye;
• • Best-corrected visual acuity of approximately 20/80 Snellen in each eye
• Exclusion Criteria:
• • Sensitivity or allergy to travoprost or timolol;
• • Bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease;
• • History of or current sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock;
• • History of cerebrovascular insufficiency;
• • Any form of glaucoma other than open-angle glaucoma
• • Advanced visual field loss or cup-to-disc ratio of 0.8 or greater
• • Non-qualifying prior surgeries or procedures in either eye